9月14日，礼来盘中上涨3.05%，报1135.78美元/股，成交额4.96亿美元。
消息面上，礼来近日宣布已正式完成对AtaiBeckley的收购。AtaiBeckley是一家临床阶段生物制药公司，专注于开发用于精神健康疾病的快速起效神经可塑性药物，核心资产包括针对难治性抑郁症的在研项目BPL-003。该交易已获AtaiBeckley股东大会批准。此外，汇丰银行近期将礼来目标价由850美元上调至940美元。据FactSet数据，分析师对礼来的平均评级为"增持"，平均目标价为1352.49美元。近期礼来在管线及商业化方面动作频频，包括Mounjaro获FDA批准新增心血管适应症、以最高28.75亿美元收购Merida Biosciences布局自身免疫领域，以及口服减重药Foundayo在英国上市等，多重利好持续提振市场信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.